MNVAEarnings•globenewswire•
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Sentiment:Negative (-20)
Summary
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire